Publication

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…

CertaraAugust 28, 2026

Webinar

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

Danielle PillsburyAugust 28, 2026

Case Study

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…

Danielle PillsburyAugust 28, 2026

Blog

The five drug development questions that bring sponsors to pharmacometrics

Sponsors rarely come to pharmacometrics because they need a model. They come with a development…

Rik de GreefAugust 24, 2026

Webinar

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Siri Kalyan ChirumamillaAugust 24, 2026

Fact Sheet

Model-Based Meta-Analysis (MBMA): Real-World Examples

See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…

CertaraAugust 24, 2026

Webinar

How to Choose Your First-in-Human Dose Approach

CertaraAugust 17, 2026

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBAAugust 14, 2026

Blog

A model-informed approach to radioligand therapy dosing under Project Optimus

Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…

Hunter Stephens, PhDAugust 13, 2026

White Paper

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…

Katie Owens, PhDAugust 12, 2026

Drug Development

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

The five drug development questions that bring sponsors to pharmacometrics

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Model-Based Meta-Analysis (MBMA): Real-World Examples

How to Choose Your First-in-Human Dose Approach

MBMA data curation: How AI and expert meta-analysts get it right, fast

A model-informed approach to radioligand therapy dosing under Project Optimus

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Newsletter sign up

Quick links

Solutions

Contact